Effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular-kidney-metabolic comorbidity

A meta-analysis of 15 trials in nearly 88,000 patients found GLP-1 receptor agonists reduced heart-failure hospitalization and cardiovascular death across heart failure, diabetes, and obesity, with a possible exception in heart failure with reduced ejection fraction.